Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 71 entries
View as:

Gene Expression Analysis of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin Based Chemotherapy Regimen

Phase: N/A Priority: Normal
NCT ID: NCT00250029 Org: User:
Start: 04/30/04 End: 03/31/06 Due: 03/31/07

The Response of Serum 25-Hydroxyvitamin D to Incidental Ultraviolet Light Exposure

Phase: N/A Priority: Normal
NCT ID: NCT00832533 Org: User:
Start: 11/30/08 End: 01/31/10 Due: 01/31/11

Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, & Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00277017 Org: User:
Start: 09/30/00 End: 08/31/05 Due: 08/31/06

Breast Cancer Screening for Underserved Women: Comparing Outcomes and Lowering Recall Rates With 3D- vs. 2D-mammography

Phase: N/A Priority: Normal
NCT ID: NCT03979729 Org: User:
Start: 09/22/16 End: 06/03/21 Due: 06/03/22

Clinical Benefit of Topoisomerase Downregulation

Phase: N/A Priority: Normal
NCT ID: NCT00250094 Org: User:
Start: 05/31/04 End: 03/31/06 Due: 03/31/07

A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec

Phase: N/A Priority: Normal
NCT ID: NCT00250042 Org: User:
Start: 04/30/04 End: 03/31/06 Due: 03/31/07

Laboratory Study of Cancer & Immune Cells in Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies

Phase: N/A Priority: Normal
NCT ID: NCT03943316 Org: User:
Start: 12/02/15 End: 12/31/27 Due: 12/31/28

Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00947739 Org: User:
Start: 09/30/08 End: 03/31/14 Due: 03/31/15

Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter

Phase: N/A Priority: Normal
NCT ID: NCT00250822 Org: User:
Start: 10/31/05 End: 07/31/06 Due: 07/31/07

Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers

Phase: N/A Priority: Normal
NCT ID: NCT00832637 Org: User:
Start: 08/31/07 End: 03/15/17 Due: 03/15/18

A Phase III Randomized Trial Assessing the Utility of a Test Dose Program With Taxanes

Phase: N/A Priority: Normal
NCT ID: NCT00277043 Org: User:
Start: 06/30/02 End: 09/30/05 Due: 09/30/06

Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01009515 Org: User:
Start: 08/31/09 End: 06/30/15 Due: 06/30/16

PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02571725 Org: User:
Start: 02/23/16 End: 07/15/27 Due: 07/15/28

Prostate Cancer Diagnosis Through NMR Spectroscopy of Semen and Prostatic Secretions

Phase: N/A Priority: Normal
NCT ID: NCT00250757 Org: User:
Start: 10/31/05 End: 04/30/12 Due: 04/30/13

Chart Review of Treatments Received by Patients Diagnosed With Soft Tissue Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT00322855 Org: User:
Start: 08/31/05 End: 08/31/07 Due: 08/31/08

A Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT01542047 Org: User:
Start: 08/31/12 End: 07/31/13 Due: 07/31/14

Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung

Phase: N/A Priority: Normal
NCT ID: NCT00391586 Org: User:
Start: 07/31/06 End: 05/31/12 Due: 05/31/13

Compassionate Use of BYL 719 Alpelisib

Phase: N/A Priority: Normal
NCT ID: NCT03941782 Org: User:
Start: - End: - Due: -

Phase II Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Tumors of the Lung

Phase: N/A Priority: Normal
NCT ID: NCT00832780 Org: User:
Start: 01/31/08 End: 12/31/18 Due: 12/31/19

Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT01032850 Org: User:
Start: 09/30/09 End: 08/31/17 Due: 08/31/18

INST 1204: PIK3CA Mutations as Biomarkers for Metastasis in Colon Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03951389 Org: User:
Start: 05/22/12 End: 10/21/19 Due: 10/21/20

Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT01009203 Org: User:
Start: 12/31/09 End: 12/31/12 Due: 12/31/13

Comparison of Standard of Care or Treatment on Protocol

Phase: N/A Priority: Normal
NCT ID: NCT01010334 Org: User:
Start: 03/31/09 End: 07/31/11 Due: 07/31/12

Clinical Predictors of Survival in Cancer Patients With Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00322634 Org: User:
Start: 02/28/06 End: 07/31/11 Due: 07/31/12

Enhancing Cancer Prevention and Control Pathways-Native Health Initiative

Phase: N/A Priority: Normal
NCT ID: NCT04259762 Org: User:
Start: 06/01/21 End: 10/31/23 Due: 10/31/24